 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
23 News |  |
- | albutropin (TV-1106) / Teva
Trial termination: A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children (clinicaltrials.gov) - May 6, 2016
P2, N=65, Terminated, Sponsor: Teva Pharmaceutical Industries
Active, not recruiting --> Terminated; Business decision
- albutropin (TV-1106) / Teva
Enrollment change, Trial termination: Study of TV-1106 in Growth Hormone-Deficient Adults (clinicaltrials.gov) - Apr 28, 2016
P3, N=14, Terminated, Sponsor: Teva Pharmaceutical Industries, Ltd.
Active, not recruiting --> Terminated; Business decision N=180 --> 14 | Active, not recruiting --> Terminated; Business decision
- albutropin (TV-1106) / Teva
Enrollment change, Trial termination: TV1106-IMM-30022: Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD) (clinicaltrials.gov) - Apr 28, 2016
P3, N=34, Terminated, Sponsor: Teva Pharmaceutical Industries, Ltd.
N=180 --> 14 | Active, not recruiting --> Terminated; Business decision N=140 --> 34 | Active, not recruiting --> Terminated; Business decision
- |||| albutropin (TV-1106) / Teva
Trial primary completion date: Study of TV-1106 in Growth Hormone-Deficient Adults (clinicaltrials.gov) - Mar 5, 2016
P3, N=180, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries, Ltd.
N=140 --> 34 | Active, not recruiting --> Terminated; Business decision Trial primary completion date: Jan 2018 --> Mar 2016
- |||| albutropin (TV-1106) / Teva
Trial primary completion date: TV1106-IMM-30022: Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD) (clinicaltrials.gov) - Mar 5, 2016
P3, N=140, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries, Ltd.
Trial primary completion date: Jan 2018 --> Mar 2016 Trial primary completion date: Mar 2017 --> Mar 2016
- || albutropin (TV-1106) / Teva
Trial primary completion date: A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children (clinicaltrials.gov) - Mar 4, 2016
P2, N=60, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries
Trial primary completion date: Mar 2017 --> Mar 2016 Trial primary completion date: Apr 2017 --> Mar 2016
- ||||| albutropin (TV-1106) / Teva
Enrollment closed: Study of TV-1106 in Growth Hormone-Deficient Adults (clinicaltrials.gov) - Feb 27, 2016
P3, N=180, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries, Ltd.
Trial primary completion date: Apr 2017 --> Mar 2016 Recruiting --> Active, not recruiting
- ||||| albutropin (TV-1106) / Teva
Enrollment closed: TV1106-IMM-30022: Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD) (clinicaltrials.gov) - Feb 27, 2016
P3, N=140, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries, Ltd.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| albutropin (TV-1106) / Teva
Enrollment closed: A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children (clinicaltrials.gov) - Oct 8, 2015
P2, N=60, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| albutropin (TV-1106) / Teva
Trial completion: TV1106-GHD-201: Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency (clinicaltrials.gov) - Aug 12, 2015
P2, N=52, Completed, Sponsor: Teva Pharmaceutical Industries
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | albutropin (TV-1106) / Teva
Enrollment open: Study of TV-1106 in Growth Hormone-Deficient Adults (clinicaltrials.gov) - Jun 11, 2015
P3, N=180, Recruiting, Sponsor: Teva Pharmaceutical Industries, Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | albutropin (TV-1106) / Teva
Enrollment open: TV1106-IMM-30022: Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD) (clinicaltrials.gov) - Jun 10, 2015
P3, N=140, Recruiting, Sponsor: Teva Pharmaceutical Industries, Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || albutropin (TV-1106) / Teva
Trial primary completion date: TV1106-GHD-201: Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency (clinicaltrials.gov) - Apr 19, 2015
P2, N=52, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2015 --> Jun 2015
- || albutropin (TV-1106) / Teva
New P3 trial, New P4 trial: Study of TV-1106 in Growth Hormone-Deficient Adults (clinicaltrials.gov) - Apr 7, 2015
P3, N=180, Not yet recruiting, Sponsor: Teva Pharmaceutical Industries, Ltd.
- || albutropin (TV-1106) / Teva
New P3 trial: TV1106-IMM-30022: Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD) (clinicaltrials.gov) - Apr 7, 2015
P3, N=140, Not yet recruiting, Sponsor: Teva Pharmaceutical Industries, Ltd.
- |||| albutropin (TV-1106) / Teva
Enrollment open: A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children (clinicaltrials.gov) - Apr 28, 2014
P2, N=60, Recruiting, Sponsor: Teva Pharmaceutical Industries
Trial primary completion date: Mar 2015 --> Jun 2015 Not yet recruiting --> Recruiting
- ||||| albutropin (TV-1106) / Teva
New P2 trial: A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children (clinicaltrials.gov) - Mar 17, 2014
P2, N=60, Recruiting, Sponsor: Teva Pharmaceutical Industries
- | albutropin (TV-1106) / Teva
Enrollment closed: TV1106-GHD-201: Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency (clinicaltrials.gov) - Jan 21, 2014
P2, N=50, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | albutropin (TV-1106) / Teva
New P2 trial: TV1106-GHD-201: Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency (clinicaltrials.gov) - Mar 12, 2013
P2, N=50, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries